Hvad er Y-tunnus-nummeret på BBS-Bioactive Bone Substitutes Oyj?

BBS-Bioactive Bone Substitutes Oyj er registreret hos PRH / YTJ under Y-tunnus 0866451-4.

Hvor mange medarbejdere har BBS-Bioactive Bone Substitutes Oyj?

BBS-Bioactive Bone Substitutes Oyj beskæftiger 3 personer pr. seneste årsrapport.

Juliusz Henrik Tadeusz Rakowski er administrerende direktør i BBS-Bioactive Bone Substitutes Oyj, i rollen siden 2023.

Pekka Kalevi Aleksanteri Jalovaara er bestyrelsesformand i BBS-Bioactive Bone Substitutes Oyj, i rollen siden 2023.

BBS-Bioactive Bone Substitutes Oyjs registrerede adresse er Kiviharjunlenkki 6.

OYJBankrupt

Y-tunnus 0866451-4Kiviharjunlenkki 6, 90220 OuluResearch and experimental development on natural sciences and engineering· NACE 7210Est. 1991 · 35 years old3 employees

Aktivt ansatte i selskabet

Name	Role	Member since
Current (1)
JH Juliusz Henrik Tadeusz Rakowski Chief Executive Officer	Chief Executive Officer	2023
Former (4)
IM Ilkka Martti Olavi Kangasniemi Chief Executive Officer	Chief Executive Officer	2019 – 2023
MJ Milla Johanna Karjalainen Deputy auditor	Deputy auditor	2020 – 2021
MJ Markku Juhani Rönkkö Audit	Audit	2017 – 2020
JP Jari Petteri Karppinen Audit	Audit	2020 – 2023

Ikke-udøvende tilsyn

Name	Role	Member since
Current (5)
GH Gregor Heinrich Siebert Board of Directors	Board of Directors	2024
JO Jarmo Olavi Halonen Board of Directors	Board of Directors	2023
PK Pekka Kalevi Aleksanteri Jalovaara Chairperson	Chairperson	2023
SJ Seppo Juhani Nevalainen Board of Directors	Board of Directors	2020
KP Kirk Patrick Andriano Board of Directors	Board of Directors	2021
Former (4)
AA Auvo Antero Juhani Kaikkonen Board of Directors	Board of Directors	2018 – 2020
HO Hannu Olavi Säynäjäkangas Board of Directors	Board of Directors	2018 – 2020
TJ Tomi Juhani Numminen Board of Directors	Board of Directors	2018 – 2021
AP Ahti Petteri Paananen Board of Directors	Board of Directors	2022 – 2024

Pr. seneste årsrapport

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.